Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Financial Rebound | Omnicell surpasses Q2 expectations, raising full-year guidance and sparking investor confidence amid improving hospital capital expenditure trends |
Strategic Evolution | Explore Omnicell's expansion into specialty pharmacy and the potential impact on Advanced Services revenue streams in a rapidly growing market segment |
Operational Overhaul | New COO appointment signals focus on cost reduction and operational efficiency, potentially driving long-term profitability and market competitiveness |
Market Positioning | Analysts set price targets ranging from $39 to $58, reflecting varied outlooks on Omnicell's ability to navigate industry challenges and capitalize on healthcare tech trends |
Metrics to compare | OMCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMCLPeersSector | |
---|---|---|---|---|
P/E Ratio | 61.6x | −4.3x | −0.7x | |
PEG Ratio | 0.30 | −0.18 | 0.00 | |
Price/Book | 1.1x | 3.7x | 2.6x | |
Price / LTM Sales | 1.2x | 3.1x | 3.4x | |
Upside (Analyst Target) | 32.5% | 28.7% | 35.5% | |
Fair Value Upside | Unlock | 3.5% | 3.3% | Unlock |